| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Diaceutics swings to loss, but reinstates guidance amid recovery in activity
StockMarketWire.com
|
Diagnostic commercialisation company Diaceutics reinstated annual guidance on recovery in US pharmaceutical sales after swinging to an annual loss in 2020.
For the year-ended 31 December 2020, the pre-tax loss was £0.7 million compared with a profit of £0.5 million year-on-year as revenue fell 6% to £12.7 million.
Looking ahead, the company reinstated guidance as activity had returned close to pre-pandemic levels by year-end.
'Recent Market data indicates that US Pharma commercial activity had returned to 95% of pre-COVID-19 levels by the end of December 2020,' the company siad.
'On balance, given the positive and cautious approach to H1 2021, the board have approved the re-instatement of guidance for 2021,' the company said.
At 9:04am: (LON:DXRX) share price was 0p at 140p
Story provided by StockMarketWire.com
|
|
|
|
|
|
